Fundamentals · 2026-09-09S&P 500ANNUAL BASIS

Gilead Sciences

GILD stock analysis · Health Care · Biotechnology

FY 2025-12-31ANNUAL FILINGS
Compare ⇄
These are research estimates based on annual filings. Valuation uses a cash-flow proxy and explicit assumptions; prices are not live. Published valuations use annual periods first filed by the price date, with later restatements retained.
Reference share price · USD
$126.34HISTORICAL SNAPSHOT

As of · fund-implied per-share value

Fund holding value ÷ shares held. Not a live quote; not adjusted for later stock splits.

View SEC fund filing ↗
Estimated issuer market cap
$156.8B

Price × SEC outstanding shares. Shares measured 2026-06-30. Approximate; share and price dates can differ.

View share-count filing ↗
Momentum data and stock-split review

The current issuer FAQ lists all five completed stock splits, ending in December 2012, and identifies the current Nasdaq GILD listing. The reviewed same-ISIN endpoint pair starts after those splits. Split multiplier 1 is an issuer-history-based inference limited to this snapshot. Cash dividends are excluded. Fund values divided by held shares are indicative price-return proxies, not exchange closes or total returns.

Issuer action history 1 ↗

Fund valuation at 2025-06-30 ↗ · Fund valuation at 2026-05-31 ↗

Valuation

DCF value

$115.73

Equity cash-flow scenario · SEC outstanding shares at 2026-06-30 · -8.4% versus input cap

How this is calculated ↗
Valuation

Reverse DCF

7.1%

Annual basis · read assumptions below

How this is calculated ↗
Valuation

Relative valuation

35.9%

6 industry peers · median 25.0×

How this is calculated ↗
Valuation

Historical multiples

20.3×

7 annual observations · snapshot P/E 18.4× · -9.3% versus history

How this is calculated ↗
Valuation

Free cash flow yield

6.0%

Annual basis · read assumptions below

How this is calculated ↗
Quality

ROIC / quality

20.8%

Normalized tax · financing-capital proxy · parent-equity fallback (scope limitation) · short-term borrowing coverage incomplete

How this is calculated ↗
Valuation

Value composite

58/100

Annual basis · read assumptions below

How this is calculated ↗
Momentum

12–1 price momentum

21.3%

2025-06-30 → 2026-05-31 · Reviewed split basis · fund snapshot

How this is calculated ↗
Investment

Asset growth

0.0%

Annual basis · read assumptions below

How this is calculated ↗
Investment

Net payout yield

3.5%

Annual basis · read assumptions below

How this is calculated ↗
Quality

Accrual quality

-2.6%

Annual basis · read assumptions below

How this is calculated ↗
Momentum

Fundamental momentum

9.0%

Annual basis · read assumptions below

How this is calculated ↗

Follow the cash

ANNUAL · USD

Operating cash flow and reinvestment over time

USD · bar maximum 11.4B2020-12-31: cfo $8,168,000,000.002020-12-31: capex $650,000,000.0020202021-12-31: cfo $11,384,000,000.002021-12-31: capex $579,000,000.0020212022-12-31: cfo $9,072,000,000.002022-12-31: capex $728,000,000.0020222023-12-31: cfo $8,006,000,000.002023-12-31: capex $585,000,000.0020232024-12-31: cfo $10,828,000,000.002024-12-31: capex $523,000,000.0020242025-12-31: cfo $10,019,000,000.002025-12-31: capex $563,000,000.002025
Operating cash flowCapital expenditure

Annual USD. Negative bars use a compressed lower scale. Hover or inspect the financial history table for exact values.

Make the assumptions yours

Personal inputs stay in this browser. Blank fields retain published inputs. Five-year forecast; zero net borrowing. Required return must exceed terminal growth.

How sensitive is the valuation?

DCF per-share sensitivity · includes reviewed preferred and minority-owner claims · rows: required return · columns: growth
Return / Growth3.0%5.0%7.0%
8.0%$145.16$158.38$172.60
10.0%$106.37$115.73$125.78
12.0%$83.92$91.06$98.72

Annual financial history

Open SEC filings ↗
Fiscal year-endRevenueNet incomeOperating cash flowCapital expenditureAssets
2025-12-3129.4B8.5B10B563M59B
2024-12-3128.8B480M10.8B523M59B
2023-12-3127.1B5.6B8B585M62.1B
2022-12-3127.3B4.6B9.1B728M63.2B
2021-12-3127.3B6.2B11.4B579M68B
2020-12-3124.7B89M8.2B650M68.4B
2019-12-3122.4B5.4B9.1B825M61.6B
2018-12-3122.1B5.5B8.4B924M63.7B

USD, abbreviated. Restated annual history; not a point-in-time backtest. Missing values appear as dashes.

Trace the inputs

MODEL ANNUAL PERIOD
InputValueSEC tag / sourceFiled
revenue29.4BRevenueFromContractWithCustomerExcludingAssessedTax2026-02-24
netIncome8.5BProfitLoss
Explicit consolidated amount, including the portion attributable to noncontrolling interests.
2026-02-24
Parent/common earnings proxy8.5BNetIncomeLoss2026-02-24
cfo10BNetCashProvidedByUsedInOperatingActivities2026-02-24
capex563MPaymentsToAcquirePropertyPlantAndEquipment2026-02-24
operatingIncome10BOperatingIncomeLoss2026-02-24
assets59BAssets2026-02-24
equity22.7BStockholdersEquity
Parent-attributable fallback: a verified consolidated total is unavailable in the supported tags. Noncontrolling interests have not been assumed to be zero; this may differ in scope from consolidated cash flow or operating income.
2026-02-24
Parent book equity proxy22.7BStockholdersEquity2026-02-24
debt24.9BLongTermDebt2026-02-24
shortDebtNot reported under a supported tag
cash7.6BCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents2026-02-24
shares1.3BWeightedAverageNumberOfDilutedSharesOutstanding2026-02-24
dividends4BPaymentsOfDividends2026-02-24
buybacks1.9BPaymentsForRepurchaseOfCommonStock2026-02-24
issuance408MProceedsFromIssuanceOfCommonStock2026-02-24